WO2023102328A3 - Treatment of cd30-positive cancer - Google Patents

Treatment of cd30-positive cancer Download PDF

Info

Publication number
WO2023102328A3
WO2023102328A3 PCT/US2022/080232 US2022080232W WO2023102328A3 WO 2023102328 A3 WO2023102328 A3 WO 2023102328A3 US 2022080232 W US2022080232 W US 2022080232W WO 2023102328 A3 WO2023102328 A3 WO 2023102328A3
Authority
WO
WIPO (PCT)
Prior art keywords
administered
dose
positive cancer
treatment
subject
Prior art date
Application number
PCT/US2022/080232
Other languages
French (fr)
Other versions
WO2023102328A2 (en
Inventor
Cliona M. Rooney
David H. Quach
Original Assignee
Baylor College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine filed Critical Baylor College Of Medicine
Publication of WO2023102328A2 publication Critical patent/WO2023102328A2/en
Publication of WO2023102328A3 publication Critical patent/WO2023102328A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Embodiments of the present disclosure provide methods of treating a CD30-positive cancer in a subject. In specific embodiments, an effective dose of CD30-specific chimeric antigen receptor (CAR)-expressing T cells are administered to the subject, wherein the dose may be administered in two parts at two time points, wherein a first part of the dose is administered at a first time point and the remaining part of the dose is administered at a second time point, wherein the first and second time points are 2 to 4 days apart.
PCT/US2022/080232 2021-12-03 2022-11-21 Treatment of cd30-positive cancer WO2023102328A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163285539P 2021-12-03 2021-12-03
US63/285,539 2021-12-03

Publications (2)

Publication Number Publication Date
WO2023102328A2 WO2023102328A2 (en) 2023-06-08
WO2023102328A3 true WO2023102328A3 (en) 2023-08-31

Family

ID=86613132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/080232 WO2023102328A2 (en) 2021-12-03 2022-11-21 Treatment of cd30-positive cancer

Country Status (2)

Country Link
TW (1) TW202339777A (en)
WO (1) WO2023102328A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200095329A1 (en) * 2018-09-24 2020-03-26 The Medical Colllege Of Wisconsin, Inc. Anti-cd30 antibodies and methods of use
WO2021222927A1 (en) * 2020-04-27 2021-11-04 Baylor College Of Medicine Virus-specific immune cells expressing chimeric antigen receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200095329A1 (en) * 2018-09-24 2020-03-26 The Medical Colllege Of Wisconsin, Inc. Anti-cd30 antibodies and methods of use
WO2021222927A1 (en) * 2020-04-27 2021-11-04 Baylor College Of Medicine Virus-specific immune cells expressing chimeric antigen receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
QUACH DAVID H., GANESH HARAN R., THAKKAR SACHIN, BECERRA-DOMINGUEZ LUIS, MEHTA BIRJU, PERCONTI SILVANA, ANDERSON ERIC, HSIEH EMILY: "A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma", BLOOD, vol. 136, no. Supplement 1, 5 November 2020 (2020-11-05), US , pages 16 - 16, XP093088292, ISSN: 0006-4971, DOI: 10.1182/blood-2020-141491 *

Also Published As

Publication number Publication date
WO2023102328A2 (en) 2023-06-08
TW202339777A (en) 2023-10-16

Similar Documents

Publication Publication Date Title
AU2018275894A1 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019220369A3 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
BR112021018442A2 (en) Multispecific antibodies egfr x cd28
JP2018523686A5 (en)
KR20220082097A (en) Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy
RS20050802A (en) Combinations for the treatment of diseases involving cell proliferation,migration or apoptosis of myeloma cells,or angiogeneis
MX2021005024A (en) Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen.
MX2021013608A (en) T cell manufacturing compositions and methods.
MX2023002544A (en) Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma.
UA86586C2 (en) Combination for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
WO2021174195A3 (en) Use of thyromimetics for the treatment of cancer
WO2020132560A3 (en) Compositions and methods for cancer therapy
WO2023102328A3 (en) Treatment of cd30-positive cancer
MX2022007779A (en) Treatment involving immune effector cells genetically modified to express antigen receptors.
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
WO2020212756A3 (en) Reprogramming of polymorphonuclear leukocytes
CL2023000437A1 (en) T cell manufacturing compositions and methods
MX2021014103A (en) Bryostatin compounds for enhancement of immunotherapy.
MX2022009041A (en) Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy.
WO2021127556A8 (en) Methods for treating cancer comprising low dose radiation
WO2020226986A3 (en) Methods of treating cancer with an anti-pd-l1 antibody
WO2022221726A3 (en) Combination therapies with bcma-directed t cell therapy
EA202191377A1 (en) METHODS FOR DOSING ENGINEERED T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANT TUMORS
WO2023164581A3 (en) Fully human monoclonal antibodies against human progranulin
MX2022006787A (en) Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22902316

Country of ref document: EP

Kind code of ref document: A2